Compare FFIC & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFIC | CSTL |
|---|---|---|
| Founded | 1929 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 510.6M | 597.8M |
| IPO Year | 1996 | 2019 |
| Metric | FFIC | CSTL |
|---|---|---|
| Price | $15.47 | $20.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $16.80 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 393.6K | 333.7K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | ★ 151.43 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | $7,455,000.00 | ★ $344,229,000.00 |
| Revenue This Year | $14.57 | $2.42 |
| Revenue Next Year | $6.64 | $12.69 |
| P/E Ratio | $91.00 | ★ N/A |
| Revenue Growth | ★ 7.31 | 3.66 |
| 52 Week Low | $11.13 | $14.59 |
| 52 Week High | $17.79 | $44.28 |
| Indicator | FFIC | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 42.77 | 46.87 |
| Support Level | $14.47 | $19.51 |
| Resistance Level | $15.55 | $24.46 |
| Average True Range (ATR) | 0.31 | 0.99 |
| MACD | -0.01 | 0.19 |
| Stochastic Oscillator | 29.46 | 41.95 |
Flushing Financial Corp is a bank holding company. Through its subsidiary, the company is engaged in attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, mainly in originations and purchases of multi-family residential properties loans, commercial business loans, commercial real estate mortgage loans and, to a lesser extent, one-to-four family loans (focusing on mixed-use properties, which are properties that contain both residential dwelling units and commercial units). It also operates an internet branch, under the brands of iGObanking.com and BankPurely. The company operates as a single unit, a community bank.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.